Affini-T Therapeutics | Unlocking the power of T cells

Affini-T is developing specific TCR-based immunotherapies for solid tumors using two complementary therapeutic modalities

Affini T Left

Affini T Middle

Affini T Right

Latest News

04.24.2025

Affini-T Therapeutics Presents Preclinical Data from its Programs Targeting Oncogenic Drivers KRAS and TP53 at AACR

Press Releases

01.09.2025

Affini-T Therapeutics to Present at the 43^rd Annual J.P. Morgan Healthcare Conference

Press Releases

11.06.2024

Affini-T Therapeutics to Present Trial-in-Progress Poster and Preclinical Data from Its Oncogenic Driver Programs Targeting TP53 R175H, KRAS G12D and KRAS-G12V at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Press Releases

05.28.2024

Affini-T Therapeutics Announces First Patient Dosed in KRAS G12V Phase 1 Program and Presentation of Trial-in-Progress Poster at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

Press Releases

Read More